GoAI
Get started
Nexalin Technology, Inc. logo

Nexalin Technology, Inc.

NXL

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.3321

+$0.0015 · +0.45%

Aug 21, 4:00 PM ET

Pre-market

$0.3321

$0.00 · 0.00%

Aug 24, 7:00 AM ET

NXL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

29

Expensive

Momentum

33

Weakening

Sentiment

51

Mixed

Risk resilience

4

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Mark White
Listed since
Sep 16, 2022
Employees
8

Market position

Day range

Current $0.3321

52-week range

Current $0.3321

Open
$0.3325
Previous close
$0.3306
Volume
88.65K
0.19× average
Average volume
476.42K
Average daily volume
Market cap
7.31M USD
Beta
4.04
Market reference 1
50-day average
$0.3853
-13.81% below average
200-day average
$0.5534
-39.99% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.49M USD
P/E (TTM)
-0.69×
P/B (TTM)
4.62×
P/S (TTM)
33.66×
EV / EBITDA
-1.04×
Earnings yield
-89.89%
Free cash flow yield
-54.20%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-148.42%
Operating margin
-4202.54%
Net margin
-4139.38%
Return on equity
-219.38%
Return on assets
-177.38%
Return on invested capital
-223.88%

Financial health

Debt / equity
0×
Current ratio
4.85×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends608%-1483%-3575%-5666%Gross margin, FY2021: 85.12%Gross margin, FY2022: 72.51%Gross margin, FY2023: 76.80%Gross margin, FY2024: 78.31%Gross margin, FY2025: 79.65%Operating margin, FY2021: -4177.70%Operating margin, FY2022: -138.72%Operating margin, FY2023: -5143.48%Operating margin, FY2024: -4596.14%Operating margin, FY2025: -2781.69%Net margin, FY2021: -4218.93%Net margin, FY2022: -128.49%Net margin, FY2023: -4197.56%Net margin, FY2024: -4508.73%Net margin, FY2025: -2725.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 85.12%. Gross margin FY2022 72.51%. Gross margin FY2023 76.80%. Gross margin FY2024 78.31%. Gross margin FY2025 79.65%. Operating margin FY2021 -4177.70%. Operating margin FY2022 -138.72%. Operating margin FY2023 -5143.48%. Operating margin FY2024 -4596.14%. Operating margin FY2025 -2781.69%. Net margin FY2021 -4218.93%. Net margin FY2022 -128.49%. Net margin FY2023 -4197.56%. Net margin FY2024 -4508.73%. Net margin FY2025 -2725.76%.

Income trends

Revenue

301.65K USD+78.78%

Operating income

−8.39M USD-8.20%

Net income

−8.22M USD-8.08%
Income trends across reported periods2.29M USD−1.59M USD−5.48M USD−9.36M USDRevenue, FY2021: 144.07K USDRevenue, FY2022: 1.32M USDRevenue, FY2023: 110.75K USDRevenue, FY2024: 168.72K USDRevenue, FY2025: 301.65K USDOperating income, FY2021: −6.02M USDOperating income, FY2022: −1.83M USDOperating income, FY2023: −5.7M USDOperating income, FY2024: −7.75M USDOperating income, FY2025: −8.39M USDNet income, FY2021: −6.08M USDNet income, FY2022: −1.7M USDNet income, FY2023: −4.65M USDNet income, FY2024: −7.61M USDNet income, FY2025: −8.22M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 144.07K USD. Revenue FY2022 1.32M USD. Revenue FY2023 110.75K USD. Revenue FY2024 168.72K USD. Revenue FY2025 301.65K USD. Operating income FY2021 −6.02M USD. Operating income FY2022 −1.83M USD. Operating income FY2023 −5.7M USD. Operating income FY2024 −7.75M USD. Operating income FY2025 −8.39M USD. Net income FY2021 −6.08M USD. Net income FY2022 −1.7M USD. Net income FY2023 −4.65M USD. Net income FY2024 −7.61M USD. Net income FY2025 −8.22M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue301.65K USD168.72K USD110.75K USD1.32M USD144.07K USD
Cost of goods sold61.37K USD36.59K USD25.69K USD363.21K USD21.44K USD
Gross profit240.27K USD132.13K USD85.06K USD958.15K USD122.62K USD
Research and development1.08M USD1.19M USD1.92M USD511K USD139K USD
Selling, general, and administrative7.55M USD6.7M USD3.86M USD2.79M USD6.14M USD
Operating expenses8.63M USD7.89M USD5.78M USD2.79M USD6.14M USD
Interest income8.24K USD3.19K USD———
Interest expense——38.84K USD59.38K USD82.32K USD
Depreciation and amortization21.54K USD15.11K USD4.25K USD5.72K USD537 USD
Operating income−8.39M USD−7.75M USD−5.7M USD−1.83M USD−6.02M USD
Net income−8.22M USD−7.61M USD−4.65M USD−1.7M USD−6.08M USD

Company facts updated Aug 24, 2026.

NXL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NXL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
42.74K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research NXL

research.disclaimer